 Can-Fite BioPharma NYSE: CANF has completed pre-clinical studies demonstrating that a Cannabidiol CBD-rich T3C15 cannabis fraction induces inhibition of liver cancer cell growth. The companys lead drug candidate Namodenoson is expected to enter the Phase 3 study in Q4 2021. 